29 August 2024 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with platinum- and fluoropyrimidine-based chemotherapy for the treatment of adults with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma.

Pembrolizumab, when used in combination with platinum- and fluoropyrimidine-based chemotherapy, is recommended as an option for the first-line treatment of adults with locally advanced, unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD‑L1 with a combined positive score (CPS) of 1 or more.

Pembrolizumab is only recommended if Merck/MSD provides it according to the commercial arrangement.

Read NICE technology appraisal guidance